Lv2
110 积分 2023-02-10 加入
Advanced AI-Driven Prediction of Pregnancy-Related Adverse Drug Reactions
2天前
已完结
Combination Therapy for EGFR-Mutated Lung Cancer
1年前
已完结
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
1年前
已完结
Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival
1年前
已完结
The Accelerated Approval Program for Cancer Drugs — Finding the Right Balance
1年前
已完结
Combined Vitamin D, Omega-3 Fatty Acids, and a Simple Home Exercise Program May Reduce Cancer Risk Among Active Adults Aged 70 and Older: A Randomized Clinical Trial
1年前
已完结
Biomarkers of aging for the identification and evaluation of longevity interventions
1年前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
1年前
已完结
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
1年前
已完结
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
1年前
已完结
皖公网安备34019202002308
